Compare Five Below Inc (FIVE) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five Below Inc vs Novavax Inc — how do they compare? Five Below Inc trades at $209.72 (market cap $11.55B), while Novavax Inc trades at $11.11 (market cap $1.82B). The key difference: Five Below Inc is far larger — about 6.3× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Five Below Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Five Below Inc for 46 Days and Novavax Inc for 59 Days on average.
| FIVE | NVAX | |
|---|---|---|
Market Cap | $11.55B | $1.82B |
Volume | 1,120,554 | 6,198,505 |
Sector | Consumer Cyclical | Health |
52-Week High | $262.72 | $12.56 |
52-Week Low | $138.49 | $6.22 |
Typical Hold Time | 46 Days | 59 Days |
Enterprise Value | $12.40B | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five Below (FIVE) trades at $204.24, down 2.71% today but maintains strong analyst support with 60% buy ratings and a $298.44 consensus price target. The company shows robust revenue growth from $3.88B in 2025 to projected $5.3B in 2026, with earnings beating expectations in three consecutive quarters. Technical indicators show bearish momentum despite oversold RSI readings, with key support at $197.
FIVE presents a compelling growth story with expanding margins and strategic initiatives, though premium valuation (P/E 18.32) and execution risks warrant caution. The stock offers significant upside to analyst targets but faces near-term technical pressure and macroeconomic headwinds affecting consumer spending.
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support (74% buy ratings). The company shows mixed fundamentals with a positive P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent developments include regulatory approvals for its updated COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with significant execution risks in the transition from COVID vaccine dependency to partnership-driven model. While valuation metrics appear attractive and technical momentum is positive, persistent negative cash flows and competitive pressures in the biotech sector warrant caution. The stock presents high-risk, high-reward potential for investors comfortable with biotech volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
